skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine

Review

(3651) Views  (1903) Full article downloads

Authors: Christopher Barone, Shaymaa S Mousa, Shaker A Mousa

Published Date September 2009 Volume 2009:2 Pages 59 - 67
DOI: http://dx.doi.org/10.2147/PGPM.S5805

Christopher Barone, Shaymaa S Mousa, Shaker A Mousa

The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA

Abstract: Some of the most commonly prescribed medications are those for cardiovascular maladies. The beneficial effects of these medications have been well documented. However, there can be substantial variation in response to these medications among patients, which may be due to genetic variation. For this reason pharmacogenomic studies are emerging across all aspects of cardiovascular medicine. The goal of pharmacogenomics is to tailor treatment to an individual’s genetic makeup in order to improve the benefit-to-risk ratio. This review examines the potential pharmacogenomic parameters which may lead to a future of personalized medicine. For example, it has been found that patients with CYP2C9 and VKORC1 gene variations have a different response to warfarin. Other studies looking at β-blockers, ACE inhibitors, ARBs, diuretics and statins have shown some results linking genetic variations to pharmacologic response. However these studies have not impacted clinical use yet, unlike warfarin findings, as the small retrospective studies need to be followed up by larger prospective studies for definitive results.

Keywords: cardiovascular, pharmacogenomics, genetics, cardiovascular medicine, personalized medicine, polymorphism






 

Other articles by Professor Shaker Mousa



Readers of this article also read:

The genetic overlap of attention deficit hyperactivity disorder and autistic spectrum disorder
Pharmacogenomics in osteoporosis: Steps toward personalized medicine
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
Gene polymorphisms in association with self-reported stroke in US adults
Impact of genetic polymorphisms on clinical response to antithrombotics
Antiplatelet agents and proton pump inhibitors – personalizing treatment
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
Role of cytochrome P450 genotype in the steps toward personalized drug therapy
The role of genetics in pre-eclampsia and potential pharmacogenomic interventions
Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era